Clinical Trials Logo

Dystonia clinical trials

View clinical trials related to Dystonia.

Filter by:

NCT ID: NCT04461730 Withdrawn - Parkinson Disease Clinical Trials

Role of Basal Ganglia and Thalamus in Perceptual Consciousness and Metacognition

METACTION
Start date: December 2021
Phase:
Study type: Observational

The term perceptual awareness refers to subjective experience... or the phenomenology associated with the processing of a sensory stimulus. The term metacognition refers to our ability of introspection, knowledge and control of our own cognitive processes. The objective of this research is to establish the contribution of the basal ganglia and thalamus to the perceptual awareness and meta-cognition, using deep brain stimulation coupled with electroencephalography.

NCT ID: NCT04432285 Enrolling by invitation - Cervical Dystonia Clinical Trials

Long-term Outcome of DBS Versus Botulinum Toxin Treatment in Cervical Dystonia

Start date: August 6, 2020
Phase:
Study type: Observational

Cervical dystonia (CD) is the most common isolated dystonia in adults. Cervical dystonia symptoms can in most patients be managed well by botulinum toxin (BTX) injections, and supporting treatment measures. However, one-fifth to one-third of patients do not obtain sufficient relief from long-term BTX therapy, resulting in reduced quality of life. Deep brain stimulation (DBS) is a treatment method in which electrodes are surgically implanted permanently in the brain to modulate brain networks and function. In cervical dystonia, DBS of the postero-ventral part of the internal globus pallidus (GPi-DBS) has been established as an effective treatment for severe cases. However, the outcome of GPi-DBS in cervical dystonia has been reported mostly in some smaller series with up to 3 years follow-up. Thus, there is a lack of documentation of outcome of GPi-DBS in CD beyond 3 years of treatment and in larger patient materials. In this study the investigators will perform a long-term follow-up study of patients who were operated with a DBS-device targeting the GPi bilaterally, and who have been treated with chronic GPi-DBS for a minimum of 3 years. The investigators will measure the severity of symptom burden and quality of life with validated rating scales. The investigators will compare this DBS-treated cohort with an age- and gender matched group of CD patients who are receiving the standard treatment with botulinum neurotoxin (BoNT) injections and have been treated for at least 3 years as well. The investigators hypothesize that the DBS-treated group will have a significantly lower burden of symptoms at long-term follow-up than the BoNT treated group.

NCT ID: NCT04421365 Recruiting - Laryngeal Dystonia Clinical Trials

Brain-Computer Interfaces in Laryngeal Dystonia

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

The researchers will develop and evaluate the use of adaptive closed-loop brain-computer interface therapeutic intervention in laryngeal dystonia.

NCT ID: NCT04348669 Recruiting - Cervical Dystonia Clinical Trials

Tele-yoga and Dystonia

Start date: April 28, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of yoga delivered remotely on adults with dystonia. This work will have implications related to physical interventions symptom management and quality of life as well as implications related to the role of tele-therapy.

NCT ID: NCT04299087 Completed - Dystonia Clinical Trials

Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor

Start date: March 12, 2020
Phase: N/A
Study type: Interventional

The study will include subjects diagnosed with Dystonic Tremor (DT), Essential Tremor (ET), and healthy controls in the age range of 21-80 years. Electroencephalography (EEG) will be used as the primary outcome measure. Transcranial Magnetic Stimulation (TMS) will be used over the motor cortices or cerebellar cortices as an intervention that is expected to have short-term (less than an hour) electrophysiological effects.

NCT ID: NCT04286308 Recruiting - Parkinson Disease Clinical Trials

Cortical-Basal Ganglia Speech Networks

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

In this research study the researchers want to learn more about brain activity related to speech perception and production.

NCT ID: NCT04283812 Withdrawn - Parkinson Disease Clinical Trials

New Stereotactic Frame System for Neurosurgery

Start date: January 2023
Phase: N/A
Study type: Interventional

This study is designed to demonstrate an in-house developed re-attachable stereotactic system that can markedly reduce the overall deep brain stimulation (DBS) procedure time to greatly facilitate subject access to neurosurgical restorative therapies. Subjects will consist exclusively of individuals who have been approved to undergo deep brain stimulation surgery for the treatment of a neurological disorder at Mayo Clinic - Rochester MN. This study is a quantitative comparative, between-subject study enrolling approximately 10 subjects.

NCT ID: NCT04277247 Recruiting - Parkinson Disease Clinical Trials

Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

Start date: January 12, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To study the effects of Botulinum toxin type A (BTXA) in the treatment of foot dystonia-associated pain in Parkinson's disease

NCT ID: NCT04270214 Active, not recruiting - Cervical Dystonia Clinical Trials

Conversion to Dysport in CD

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The first line of therapy for cervical dystonia patients is botulinum toxin injections, however injection parameter determination and optimization are challenging for physicians to do. In addition, some patients receiving this treatment long-term experience short duration of relief. Thus, Dysport (Ipsen Biopharmaceuticals), another BoNT-A formulation, may increase the duration of clinical benefit. The objective of this study is to compare the wearing off time of their original BoNT-A formulation (same injection parameters for at least 3 cycles) and the optimized treatment of Dysport (after 2 injection cycles). Ideally, the clinical benefits should last 2.5 - 3 months as injections are administered every 3 months. Conversion to Dysport will be conducted and optimization of Dysport dosing will be done using our sensor-technology assessment. It is unclear whether there are differences in the neurophysiological effects between BoNT-A formulations, such as blocking spinal afferent signals from proprioceptive mechanoreceptors of the injected muscles contributing to CD or the modulation of cortical activity [8]. The underlying pathophysiology of impaired motor control in CD is theorized to be caused by abnormal somatosensory processing that affects proprioceptive and tactile function [8]. By altering the processing of proprioceptive signals from the muscles to the cortical somatosensory-motor areas, proprioceptive perception can be modulated and possibly normalize activity of the somatosensory-motor areas in CD. Thus, it is hypothesized that BoNT-A may indirectly modulate these cortical pathways and Dysport may have a longer modulatory effect to produce a longer lasting clinical response.

NCT ID: NCT04231487 Recruiting - Parkinson Disease Clinical Trials

Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders

Start date: June 27, 2019
Phase:
Study type: Observational

The purpose of the research is to better understand the motor behavior of individuals in health and disease. The specific purpose of this project is to identify if we can utilize a smartphone to diagnose different movement disorders and monitor their symptoms. A. Objectives 1. Estimate symptom severity of Essential tremor (ET), Parkinson's disease (PD), Huntington's disease (HD), Primary focal dystonia (PFD), spinocerebellar ataxia (SCA), and Functional movement disorders (FMD) using a smartphone-based application 2. Differentiate individuals with the different movement disorders from healthy controls based on features from the smartphone data 3. Differentiate individuals with a specific movement disorder from people with other movement disorders based on features from the smartphone data B. Hypotheses / Research Question(s) We hypothesize that we can estimate the severity of symptoms using a smartphone application and that, using those estimates, we can differentiate individuals with movement disorders from healthy controls and from people with other movement disorders.